Related references
Note: Only part of the references are listed.Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Daniel Bloomfield et al.
AMERICAN HEART JOURNAL (2009)
Safety and Tolerability of Dalcetrapib
Evan A. Stein et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Long-term Benefit of High-Density Lipoprotein Cholesterol-Raising Therapy With Bezafibrate 16-Year Mortality Follow-up of the Bezafibrate Infarction Prevention Trial
Ilan Goldenberg et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway
Giovanna Catalano et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters Relevance to Antioxidative Function
W. Sean Davidson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott et al.
DIABETES CARE (2009)
Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes
Renato D. Lopes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia
Frank Hermann et al.
THROMBOSIS RESEARCH (2009)
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
John F. Paolini et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and apoB-containing lipoproteins
Stefania Lamon-Fava et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Of Mice and Men Blowing Away the Cobwebs From the Mechanism of Action of Niacin on HDL Metabolism
G. F. Watts et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
Jose W. A. van der Hoorn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia
Maryse Guerin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Philip J. Barter et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit
Fergus McTaggart et al.
CARDIOVASCULAR DRUGS AND THERAPY (2008)
Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials
Menno Vergeer et al.
CIRCULATION (2008)
Combined statin and niacin therapy remodels the high-density lipoprotein proteome
Pattie S. Green et al.
CIRCULATION (2008)
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Stephen J. Nicholls et al.
CIRCULATION (2008)
Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque
James A. Shaw et al.
CIRCULATION RESEARCH (2008)
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels (Reprinted from Heart, vol 94, pg 706-14, 2008)
D. J. Hausenloy et al.
POSTGRADUATE MEDICAL JOURNAL (2008)
Molecular processes that handle - and mishandle - dietary lipids
Kevin Jon Williams
JOURNAL OF CLINICAL INVESTIGATION (2008)
Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL
Lin-Hua Zhang et al.
JOURNAL OF LIPID RESEARCH (2008)
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk - The IDEAL and EPIC-Norfolk studies
Wim A. van der Steeg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
Michael Miller et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Is raising HDL a futile strategy for atheroprotection?
Tisha Joy et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Spotlight on HDL-raising therapies:: insights from the torcetrapib trials
Anatol Kontush et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Fibrates and future PPAR alpha agonists in the treatment of cardiovascular disease
Bart Staels et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
D. J. Hausenloy et al.
HEART (2008)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials
Sandeep Ajoy Saha et al.
AMERICAN HEART JOURNAL (2007)
Apolipoprotein A-II is inversely associated with risk of future coronary artery disease
Rakesh S. Birjmohun et al.
CIRCULATION (2007)
High-density lipoprotein as a therapeutic target - A systematic review
Inder M. Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Sandeep Bansal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Borge G. Nordestgaard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Michiel L. Bots et al.
LANCET (2007)
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL
Laurent Yvan-Charvet et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice
Melba Hernandez et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins
Bela F. Asztalos et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules
Xiayang Qiu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL
Tomas Vaisar et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
Michael H. Davidson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation
Roswitha M. Wolfram et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Insulin resistance and atherosclerosis
Clay F. Semenkovich
JOURNAL OF CLINICAL INVESTIGATION (2006)
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans
John S. Millar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators -: Clinical and experimental evidence
A Zambon et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Antiatherogenic small, dense HDL - guardian angel of the arterial wall?
A Kontush et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2006)
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
RW Clark et al.
JOURNAL OF LIPID RESEARCH (2006)
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
PJ Barter et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis
Anatol Kontush et al.
PHARMACOLOGICAL REVIEWS (2006)
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
M. John Chapman
PHARMACOLOGY & THERAPEUTICS (2006)
High-density lipoprotein function - Recent advances
BJ Ansell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
The forgotten majority - Unfinished business in cardiovascular risk reduction
P Libby
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Clinical practice: Low HDL cholesterol levels
MD Ashen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review
LA Carlson
JOURNAL OF INTERNAL MEDICINE (2005)
Niaspan®:: creating a new concept for raising HDL-cholesterol
M McGovern
EUROPEAN HEART JOURNAL SUPPLEMENTS (2005)
New insights into the regulation of HDL metabolism and reverse cholesterol transport
GF Lewis et al.
CIRCULATION RESEARCH (2005)
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion
ME Brousseau et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation
H Duez et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials
RS Birjmohun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly
JD Curb et al.
JOURNAL OF LIPID RESEARCH (2004)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib
RW Clark et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin
T Rubic et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity
B Hansel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans
CC Schwartz et al.
JOURNAL OF LIPID RESEARCH (2004)
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C
MJ Chapman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia
W Le Goff et al.
PHARMACOLOGY & THERAPEUTICS (2004)
Benefit-risk assessment of rosuvastatin 10 to 40 milligrams
HB Brewer
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Action of ciprofibrate in type IIB hyperlipoproteinemia: Modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux
M Guerin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease - The Diabetes Atherosclerosis Intervention Study (DAIS)
J Vakkilainen et al.
CIRCULATION (2003)
Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis
PJ Barter et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia
ZP Huang et al.
CLINICAL SCIENCE (2002)
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)
L Streja et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state
M Guerin et al.
JOURNAL OF LIPID RESEARCH (2002)
Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease -: The PRIME Study
G Luc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation
S Rashid et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions - The Atherosclerosis Risk in Communities (ARIC) Study
AR Sharrett et al.
CIRCULATION (2001)
Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
SJ Robins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Proatherogenic role of elevated CE transfer from HDL to VLDL1 and dense LDL in type 2 diabetes -: Impact of the degree of triglyceridemia
M Guérin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
G Chinetti et al.
NATURE MEDICINE (2001)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Action of atorvastatin in combined hyperlipidemia - Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
M Guerin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
